Spain Liquid Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Technology (Multi-Gene-Parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays)), By Biomarker (Circulating Tumor Cells (CTCs), Circulating Nucleic Acids, Exosomes/Microvesicles, and Circulating Proteins), By Application (Cancer, Reproductive Health, and Others), and Spain Liquid Biopsy Market Insights, Industry Trend, Forecasts to 2033

Spain Liquid Biopsy Market Insights Forecasts to 2033

• The Spain Liquid Biopsy Market Size was valued at USD 198.5 Million in 2023.
• The Spain Liquid Biopsy Market Size is Growing at a CAGR of 10.86% from 2023 to 2033
• The Spain Liquid Biopsy Market Size is Expected to reach USD 556.5 Million by 2033

The Spain Liquid Biopsy Market Size is Anticipated to Exceed USD 556.5 Million by 2033, Growing at a CAGR of 10.86% from 2023 to 2033. The growing prevalence of cancer, increasing research publications, and clinical trials are driving the growth of the liquid biopsy market in the Spain.     

Market Overview

The liquid biopsy market is the industry encompassing non-invasive diagnostic tests that analyze bodily fluids (like blood) to detect cancer or other diseases, offering insights into diseases with the need for traditional tissue biopsies. A liquid biopsy is a non-invasive diagnostic test that detects signs of a cancerous tumor, including tumor cells and cancer cell DNA. It enables real-time tumor monitoring and facilitates the tracking of resistance development to specific therapies, which provide crucial insights for cancer treatment. The inclination towards the use of minimally invasive cancer diagnostics and ongoing research for liquid biopsy assays and tests aids in the adoption and development of detection tests for multiple types of cancer. Development of new technologies and application of liquid biopsy in clinical settings in the field of cancer diagnosis for cancer management is providing market growth opportunities.

Report Coverage

This research report categorizes the market for the Spain liquid biopsy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Spain liquid biopsy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Spain liquid biopsy market.

Driving Factors

The use of liquid biopsy for detecting the signs of cancerous tumors, including tumor cells and cancer cell DNA, is propelling the liquid biopsy market. In Spain, the estimated cancer cases in 2024 is 286,664, and is found to be the leading cause of death. The increasing research publications exploring the trend and prospects in liquid biopsy for cancer are expected to propel the market. The rapid growth of liquid biopsies and their incorporation into various clinical trials are contributing to propelling the market.

Restraining Factors

The lack of standardized testing protocols and the availability of alternative diagnostic methods are likely to hamper the market. Further, the challenges associated with the regulatory approvals are hindering market growth.

Market Segmentation

The Spain liquid biopsy market share is classified into technology, biomarker, and application.

• The multi-gene-parallel analysis (NGS) segment dominated the market with the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR during the projected period.

The Spain liquid biopsy market is segmented by technology into multi-gene-parallel analysis (NGS) and single gene analysis (PCR microarrays). Among these, the multi-gene-parallel analysis (NGS) segment dominated the market with the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR during the projected period. Multi-gene-parallel analysis technology of liquid biopsy involves the simultaneous analysis of multiple genes from cfDNA to detect mutations for tumor diagnosis, monitoring, and treatment response assessment. The development of NGS technology for reducing the cost of high accuracy sequencing is propelling the market growth.

• The circulating nucleic acids segment is dominating the market with the largest market share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

The Spain liquid biopsy market is segmented by biomarker into circulating tumor cells (CTCs), circulating nucleic acids, exosomes/microvesicles, and circulating proteins. Among these, the circulating nucleic acids segment is dominating the market with the largest market share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. Circulating nucleic acid biomarkers include DNA, RNA, proteins, exosomes, and metabolites and are often used for non-invasive diagnostic purposes, providing valuable insights into disease states like cancer. The discovery of ctDNA, offering the opportunity for liquid biopsy application for cancer diagnosis, is driving market growth.

•  The cancer segment is dominating the market with the largest revenue share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

The Spain liquid biopsy market is segmented by application into cancer, reproductive health, and others. Among these, the cancer segment is dominating the market with the largest revenue share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. Liquid biopsy is increasingly used for cancer molecular profiling, enabling a precision oncology approach. The increasing adoption of liquid biopsy in cancer detection with the growing prevalence of cancer is propelling the market demand.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Spain liquid biopsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• OncoOne
• PCR Diagnostics
• Illumina
• Thermo Fisher Scientific
• Navan Health
• Sysmex Corporation
• Biocept
• Foundation Medicine
• Guardant Health
• Exosome Diagnostics
• Qiagen
• F. HoffmannLa Roche
• GRAIL
• Strata Oncology
• Cynvenio
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In October 2023, Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, advances its mission with a first release of groundbreaking scientific data at the European Society for Medical Oncology (ESMO) Congress 2023.

Market Segment

This study forecasts revenue at Spain, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Spain liquid biopsy market based on the below-mentioned segments:

Spain Liquid Biopsy Market, By Technology

• Multi-Gene-Parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Spain Liquid Biopsy Market, By Biomarker   

• Circulating Tumor Cells (CTCs)
• Circulating Nucleic Acids
• Exosomes/Microvesicles
• Circulating Proteins

Spain Liquid Biopsy Market, By Application

• Cancer
• Reproductive Health
• Others